15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Telix Pharmaceuticals Limited, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $20.00 to $22.00, so the covering firms are broadly aligned. The average target of $21.00 sits 75% above the current $11.99. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.00 next quarter toward $0.20 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Telix Pharmaceuticals Limited.
As of Sep, 3 of 3 firms rate TLX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TLX EPS & revenue forecast
EPS · NEXT QUARTER
$0.00
Range $0.00 – $0.00 · 1 analysts
Next period, 1 analysts expect Telix Pharmaceuticals Limited to earn $0.00 a share (range $0.00 – $0.00), versus — a year earlier. Full-year consensus is $0.15, growing to $0.20 the year after.
REVENUE · NEXT QUARTER
$351.7M
Range $351.7M – $351.7M · 1 analysts · +14% YoY
Revenue is expected to reach $351.7M (range $351.7M – $351.7M), +13.5% year-over-year. Full-year consensus is $1.4B, rising to $1.6B next year.
Top analysts covering Telix Pharmaceuticals Limited
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TLX.
#1
David Nierengarten
Wedbush · Rank #66
Buy
$22.00+83.5% to target
Overall win rate
42%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #199
Buy
$20.00+66.8% to target
Overall win rate
41%
+ Follow
#3
LS
Laura Sutcliffe
Citigroup
Buy
$22.00+83.5% to target
Coverage
—
+ Follow
#4
LS
Laura Sutcliffe
UBS
Buy
$22.00+83.5% to target
Coverage
—
+ Follow
#5
DD
David Dai
UBS
Buy
$20.00+66.8% to target
Coverage
—
+ Follow
TLX stock forecast FAQ
What is TLX's average 12-month price target?+
The 4 analysts with a live target average $21.00 for Telix Pharmaceuticals Limited over the next 12 months, ranging from a $22.00 high to a $20.00 low.
Is TLX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TLX?+
The Street-high target is $22.00 (Wedbush), and the Street-low is $20.00 (HC Wainwright & Co.). The average of all 4 active targets is $21.00.
How many Wall Street analysts cover TLX?+
4 analysts have an active rating on Telix Pharmaceuticals Limited, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering TLX?+
Among analysts who currently cover TLX, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #66). Their current call is Buy with a $22.00 target.
What is Telix Pharmaceuticals Limited's projected EPS for next quarter?+
The consensus estimate is $0.00 per share (range $0.00 – $0.00) across 1 analysts. Full-year EPS is projected at $0.15, rising to $0.20 the following year.
How much revenue is Telix Pharmaceuticals Limited expected to report next quarter?+
Consensus revenue is $351.7M (range $351.7M – $351.7M). Full-year revenue is projected at $1.4B, growing to $1.6B next year.
Have analysts been upgrading or downgrading TLX lately?+
As of Sep, 3 of 3 firms rate TLX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TLX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
